National Institutes of Health
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification
About This Grant
The National Institute of Neurological Disorders and Stroke, National Institute of Aging, the NIH Helping to End Addiction Long Term (HEAL) initiative , and other participating NIH Institutes/Centers (ICs) seek to support applications to develop in vitro, ex vivo or in vivo assays and conduct screening efforts with the goal of identifying and characterizing potential therapeutic agents for disorders or diseases supported by participating ICs, or for non-opioid analgesic therapeutics with little or no addiction liability as a part of the NIH Helping to End Addiction Long Term (HEAL) initiative . Therapeutic agents include small molecules and biologics. Assays utilizing New Approach Methodologies (NAMs) may be used when appropriate. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
Who Can Apply
Focus Areas
Additional Details
- CFDA / ALN Number
- 93.853
- Program Title
- Extramural Research Programs in the Neurosciences and Neurological Disorders
- Source
- Grants.gov · View original listing
Similar Grants
Center for Medicare and Medicaid Services
Make America Healthy Again – Enhancing Lifestyle and Evaluating Value-based Approaches Through Evidence
Up to $3.3MDue in 7 days — May 15, 2026Centers for Disease Control and Prevention - ERA
Occupational Safety and Health Education and Research Centers (T42)
$4.5M – $9MDue October 26, 2028National Institutes of Health
Risk and Protective Factors of Family Health and Family Level Interventions (R01 Clinical Trial Optional)
Due May 8, 2027National Institutes of Health
Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)
Due June 1, 2027National Institutes of Health
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
Due November 18, 2026National Institutes of Health
Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
Due January 7, 2028